Patient characteristics at diagnosis and index therapy
| . | At diagnosis (N = 220) . | At index therapy (N = 220) . |
|---|---|---|
| Age, median (IQR) | 56 (48-64) | 58 (49-66) |
| Gender | ||
| Male | 128 (58%) | — |
| Female | 92 (42%) | — |
| Race | ||
| White | 174 (79%) | — |
| African American | 8 (4%) | — |
| Other | 11 (5%) | — |
| Unknown | 27 (12%) | — |
| Stage | ||
| I-II | 16 (8%) | 21 (12%) |
| III-IV | 182 (92%) | 161 (88%) |
| Missing | 22 | 38 |
| Histologic grade | ||
| Grade 1-2 | 177 (80%) | 161 (73%) |
| Grade 3A | 32 (15%) | 39 (18%) |
| Unknown 1-3A | 11 (5%) | 20 (9%) |
| Year of diagnosis | ||
| 2002-2010 | 87 (40%) | — |
| 2011-2020 | 133 (60%) | — |
| Eastern cooperative group PS | ||
| 0-1 | 136 (92%) | 155 (97%) |
| 2-4 | 12 (8%) | 4 (3%) |
| Missing | 72 | 61 |
| B symptoms | ||
| None reported | 219 (86%) | 245 (96%) |
| Yes | 37 (14%) | 11 (4%) |
| Lactated dehydrogenase | ||
| Not elevated | 83 (61%) | 92 (68%) |
| Elevated | 53 (39%) | 44 (32%) |
| Missing | 84 | 84 |
| Hemoglobin | ||
| <12 | 35 (25%) | 35 (23%) |
| >12 | 106 (75%) | 120 (77%) |
| Missing | 79 | 65 |
| Number of nodal groups | ||
| 0-4 | 68 (37%) | 110 (60%) |
| >4 | 115 (63%) | 72 (40%) |
| Missing | 37 | 38 |
| Bulky disease | ||
| No | 119 (72%) | 135 (85%) |
| Yes | 46 (28%) | 24 (15%) |
| Missing | 55 | 61 |
| Bone marrow involvement | ||
| Yes | 105 (59%) | 38 (29%) |
| No | 73 (41%) | 93 (71%) |
| Missing | 42 | 89 |
| FLIPI | ||
| 0-1 | 24 (17%) | 34 (26%) |
| 2 | 46 (33%) | 46 (35%) |
| 3-5 | 69 (50%) | 51 (39%) |
| Missing | 81 | 89 |
| GELF criteria | ||
| ≥1 GELF criteria | 100 (45%) | 74 (34%) |
| No reported GELF criteria | 120 (55%) | 146 (66%) |
| Treatment location | ||
| LEO Center | 91 (43%) | 124 (58%) |
| Other center | 122 (57%) | 91 (42%) |
| Missing | 7 | 5 |
| Clinical trial status | ||
| Treated on trial | 7 (3%) | 40 (19%) |
| Not on trial | 199 (97%) | 169 (81%) |
| Missing | 14 | 11 |
| . | At diagnosis (N = 220) . | At index therapy (N = 220) . |
|---|---|---|
| Age, median (IQR) | 56 (48-64) | 58 (49-66) |
| Gender | ||
| Male | 128 (58%) | — |
| Female | 92 (42%) | — |
| Race | ||
| White | 174 (79%) | — |
| African American | 8 (4%) | — |
| Other | 11 (5%) | — |
| Unknown | 27 (12%) | — |
| Stage | ||
| I-II | 16 (8%) | 21 (12%) |
| III-IV | 182 (92%) | 161 (88%) |
| Missing | 22 | 38 |
| Histologic grade | ||
| Grade 1-2 | 177 (80%) | 161 (73%) |
| Grade 3A | 32 (15%) | 39 (18%) |
| Unknown 1-3A | 11 (5%) | 20 (9%) |
| Year of diagnosis | ||
| 2002-2010 | 87 (40%) | — |
| 2011-2020 | 133 (60%) | — |
| Eastern cooperative group PS | ||
| 0-1 | 136 (92%) | 155 (97%) |
| 2-4 | 12 (8%) | 4 (3%) |
| Missing | 72 | 61 |
| B symptoms | ||
| None reported | 219 (86%) | 245 (96%) |
| Yes | 37 (14%) | 11 (4%) |
| Lactated dehydrogenase | ||
| Not elevated | 83 (61%) | 92 (68%) |
| Elevated | 53 (39%) | 44 (32%) |
| Missing | 84 | 84 |
| Hemoglobin | ||
| <12 | 35 (25%) | 35 (23%) |
| >12 | 106 (75%) | 120 (77%) |
| Missing | 79 | 65 |
| Number of nodal groups | ||
| 0-4 | 68 (37%) | 110 (60%) |
| >4 | 115 (63%) | 72 (40%) |
| Missing | 37 | 38 |
| Bulky disease | ||
| No | 119 (72%) | 135 (85%) |
| Yes | 46 (28%) | 24 (15%) |
| Missing | 55 | 61 |
| Bone marrow involvement | ||
| Yes | 105 (59%) | 38 (29%) |
| No | 73 (41%) | 93 (71%) |
| Missing | 42 | 89 |
| FLIPI | ||
| 0-1 | 24 (17%) | 34 (26%) |
| 2 | 46 (33%) | 46 (35%) |
| 3-5 | 69 (50%) | 51 (39%) |
| Missing | 81 | 89 |
| GELF criteria | ||
| ≥1 GELF criteria | 100 (45%) | 74 (34%) |
| No reported GELF criteria | 120 (55%) | 146 (66%) |
| Treatment location | ||
| LEO Center | 91 (43%) | 124 (58%) |
| Other center | 122 (57%) | 91 (42%) |
| Missing | 7 | 5 |
| Clinical trial status | ||
| Treated on trial | 7 (3%) | 40 (19%) |
| Not on trial | 199 (97%) | 169 (81%) |
| Missing | 14 | 11 |
GELF, Groupe d'Etude des Lymphomes Folliculaires.